title: Therapeutic efficacy of sulfadoxine-pyrimethamine for Plasmodium falciparum malaria.
abstract: OBJECTIVE
  To assess the therapeutic efficacy of sulfadoxinepyrimethamine (SP) after 5 years of use as first-line treatment of uncomplicated Plasmodium falciparum malaria, and thus guide the selection of artemisinin-based combination therapy in Mpumalanga, South Africa.
  
  
  METHODS
  An open-label, in vivo therapeutic efficacy study of patients with uncomplicated P. falciparum malaria treated with a single oral dose of SP, with response to treatment monitored clinically and parasitologically on days 1, 2, 3, 7, 14, 21, 28 and 42.
  
  
  METHODS
  Mangweni and Naas public health care clinics, Tonga district in rural Mpumalanga. SUBJECTS, OUTCOME MEASURES AND RESULTS: Of 152 patients recruited sequentially, 149 (98%) were successfully followed up for 42 days. One hundred and thirty-four patients (90%) demonstrated adequate clinical and parasitological response. Of the 15 patients (10%) who failed treatment, 2 (1.3%) had an early treatment failure, and polymerase chain reaction confirmed recrudescent infection in all 13 patients (8.7%) who had late parasitological (N = 11) or clinical (N = 2) failure. Gametocyte carriage was prevalent following SP treatment (84/152) and this has increased significantly since implementation in 1998 (relative risk 2.77 (confidence interval 1.65 - 4.66); p = 0.00004).
  
  
  CONCLUSIONS
  Asexual P. falciparum parasites in Mpumalanga remain sensitive to SP, with no significant difference between the baseline cure rate (94.5%) at introduction in 1998, and the present 90% cure rate (p = 0.14). However, since gametocyte carriage has increased significantly we recommend that SP be combined with artesunate in Mpumalanga to reduce gametocyte carriage and thus decrease malaria transmission and potentially delay antimalarial resistance.
authors.affiliation: Malaria Control Programme, Mpumalanga Provincial Department of Health, Nelspruit, South Africa.
authors.forename: A
authors.initials: A
authors.lastname: Mabuza
authors.forename: J
authors.initials: J
authors.lastname: Govere
authors.forename: K
authors.initials: K
authors.lastname: La Grange
authors.forename: N
authors.initials: N
authors.lastname: Mngomezulu
authors.forename: E
authors.initials: E
authors.lastname: Allen
authors.forename: A
authors.initials: A
authors.lastname: Zitha
authors.forename: F
authors.initials: F
authors.lastname: Mbokazi
authors.forename: D
authors.initials: D
authors.lastname: Durrheim
authors.forename: K
authors.initials: K
authors.lastname: Barnes
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D002648:Child; D004338:Drug Combinations; D005260:Female; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D010963:Plasmodium falciparum / Q000187:drug effects; D015995:Prevalence; D011739:Pyrimethamine / Q000627:therapeutic use*; D013019:South Africa / Q000453:epidemiology; D013413:Sulfadoxine / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine